Table 5.
Associations with COVID-19 infection severity in the subgroup of patients at higher risk of severe forms of COVID-19a.
| Predictors |
Sotrovimab |
Controls |
Severe/critical/fatalbCOVID-19 vs. mild/asymptomatic infection |
|||||
|---|---|---|---|---|---|---|---|---|
| Total sample | Severe/critical/fatalbCOVID-19 | Total sample | Severe/critical/fatalbCOVID-19 |
Univariable regression analysis |
Multivariable regression analysis |
|||
| N (%) | N (%c) | N (%) | N (%c) | OR (95% CI) | P-value | AOR (95% CI) | P-value | |
| Study group | ||||||||
| Control | - | - | 1,043 (100.0) | 9 (0.9) | 1.00 | 1.00 | ||
| Sotrovimab | 340 (100.0) | 7 (2.1) | - | - | 2.42 (0.89-6.53) | 0.083 | 1.33 (0.44-4.05) | 0.618 |
| Vaccination statusd | ||||||||
| Unvaccinated | 153 (45.0) | 4 (2.6) | 658 (63.1) | 5 (0.8) | 1.00 | 1.00 | ||
| Two doses | 145 (42.6) | 3 (2.1) | 287 (27.5) | 3 (1.0) | 1.26 (0.44-3.55) | 0.668 | 1.52 (0.49-4.70) | 0.468 |
| Three doses | 42 (12.4) | 0 (0.0) | 98 (9.4) | 1 (1.0) | 0.64 (0.08-5.10) | 0.674 | 0.58 (0.07-5.16) | 0.626 |
| Prior infection statusd | ||||||||
| No | 312 (91.8) | 7 (2.2) | 953 (91.4) | 9 (0.9) | 1.00 | 1.00 | ||
| Yes | 28 (8.2) | 0 (0.0) | 90 (8.6) | 0 (0.0) | 1.00 (1.00-1.00) | - | 1.00 (1.00-1.00) | - |
| Age (years) | ||||||||
| <75 | 308 (90.6) | 5 (1.6) | 1,031 (98.8) | 8 (0.8) | 1.00 | 1.00 | ||
| ≥75 | 32 (9.4) | 2 (6.3) | 12 (1.2) | 1 (8.3) | 7.46 (2.05-27.20) | 0.002 | 6.92 (1.50-32.02) | 0.013 |
| Sex | ||||||||
| Male | 100 (29.4) | 2 (2.0) | 274 (26.3) | 4 (1.5) | 1.00 | 1.00 | ||
| Female | 240 (70.6) | 5 (2.1) | 769 (73.7) | 5 (0.7) | 0.61 (0.22-1.70) | 0.348 | 0.61 (0.21-1.74) | 0.357 |
| Nationality | ||||||||
| Qatari | 116 (34.1) | 2 (1.7) | 483 (46.3) | 3 (0.6) | 1.00 | 1.00 | ||
| Craft and manual worker nationalitiese | 74 (21.8) | 2 (2.7) | 159 (15.2) | 0 (0.0) | 1.03 (0.20-5.34) | 0.973 | 1.22 (0.21-6.94) | 0.822 |
| Other nationalities | 150 (44.1) | 3 (2.0) | 401 (38.4) | 6 (1.5) | 1.97 (0.66-5.92) | 0.226 | 2.01 (0.62-6.57) | 0.246 |
| Epidemic phasef | ||||||||
| Delta-dominated incidence | 104 (30.6) | 4 (3.8) | 172 (16.5) | 4 (2.3) | 1.00 | 1.00 | ||
| Omicron-dominated incidence | 236 (69.4) | 3 (1.3) | 871 (83.5) | 5 (0.6) | 0.24 (0.09-0.66) | 0.005 | 0.30 (0.10-0.88) | 0.028 |
Abbreviations: AOR, adjusted odds ratio; OR, odds ratio.
These include immunocompromised individuals (solid organ or hematopoietic stem cell transplant recipients, patients receiving chemotherapy or immunosuppressive treatments, patients with severe immunodeficiency, and HIV patients), unvaccinated individuals, those ≥75 years of age, and pregnant women.
Severity (2021), criticality (2021), and fatality (2021) were defined according to the World Health Organization guidelines.
Proportion of those who progressed to severe, critical, or fatal COVID-19 among those in the predictor category.
Vaccination status and prior infection status were ascertained at the time of infection.
These include Bangladeshis, Indians, Nepalese, Pakistanis, Sri Lankans, and Sudanese due to large proportions of these nationals being craft and manual workers.
Before December 19, 2021 incidence in Qatar was dominated by the Delta variant, whereas starting from December 19, 2021 incidence was dominated by the Omicron variant.